April 19, 2019 at 3:03 am

EPS Growth of -34.90% at Forefront For Anika Therapeutics, Inc. (NASDAQ:ANIK)


For the next year, sell-side analysts are expecting EPS growth of -2.32% for Anika Therapeutics, Inc. (NASDAQ:ANIK). Analysts are expecting an EPS change of -34.90% for the current year.

Wall Street analysts polled by Thomson Reuters have a current recommendation of 2.20 on a consensus basis for the stock. The same analysts see shares reaching $40.25 within the next year on a consensus basis.High yielding stocks can be very tempting for investors. Trying to maximize the return on every dollar invested is a goal of many individuals. What investors have to remember is that the stocks that promise the highest return potential may also be some of the riskiest to own. Because past performance can’t guarantee future results, investors may need to do some extra research when adding high risk stocks to the portfolio. Most investors are always on the lookout to spot that next big stock winner before everyone else. Making sure that they are not adding too much extra risk when doing this may be the key to keeping the portfolio balanced. 

Let’s take a look at how the stock has been performing recently.  Over the past twelve months, Anika Therapeutics, Inc. (NASDAQ:ANIK)’s stock was -5.86%.  Over the last week of the month, it was -0.85%, -9.86% over the last quarter, and  -25.04% for the past six months.

Over the past 50 days, Anika Therapeutics, Inc. stock’s -22.28% off of the high and 9.07% removed from the low.  Their 52-Week High and Low are noted here.  -32.09% (High), 10.86%, (Low). 


Fundamental analysis examines the financial elements of a company, for example; sales, cash flow, profit and balance sheet.  These numbers are then crunched to create theoretical valuations of companies. 

Earnings Per Share (EPS) is the earnings made by a company divided by their number of shares.  EPS enables the earnings of a company to easily be compared to their competitors. The higher the number, the more profit per dollar is being made on investor capital.  Anika Therapeutics, Inc.’s EPS for the trailing 12 months is 1.29.  Their EPS should be compared to other companies in the Healthcare sector.

Price-to-Earnings Ratio is the current share price divided by annual earnings per share.  P/E provides a number that details how many years of earnings it will take a stock to recoup the value of one share at current price levels.  Easy to calculate and understand, P/E is an extremely common ratio that is used to compare valuations of stocks against each other relatively.  Anika Therapeutics, Inc.’s  P/E ratio is 24.53. 

Technical analysts have little regard for the value of a company. They use historic price data to observe stock price patterns to predict the direction of that price going forward.  Analysts use common formulas and ratios to accomplish this.

Anika Therapeutics, Inc. (NASDAQ:ANIK)’s RSI (Relative Strength Index) is 45.22.  RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions.

Stock market investing can sometimes become highly emotional. Being able to leave emotions out of the major investing decisions might be tricky, but it may end up being a portfolio savior down the road. Nobody wants to see a thoroughly researched stock pick underperform. Holding onto the hope that a certain stock has to bounce back may lead to later problems. Of course, it can be very hard for humans to admit when a mistake was made. Finding the ability to detach from a position can be tough. Humans make mistakes, but being able to learn from those mistakes moving forward can help with achieving long term success in the market.